Anti-Cytochrome P450 1B1 [5D3]

Recent studies have highlighted the potential of this enzyme as a novel cancer therapeutic target, resulting in several clinical development programs focused on CYP1B1-activated prodrugs and CYP1B1 inhibitors.

Contributors

Inventor Institute
Ayham Alnabulsi Vertebrate Antibodies Limited
Cat. #: 153656
Tool sub type: Primary antibody
Unit size: 100 ug
Cancer types: Ovarian cancer;Breast cancer;Prostate cancer
Research Fields: Cancer;Cell signaling and signal transduction;Metabolism;Neurobiology;Tissue-specific biology
Application: ELISA ; IHC ; WB
Target: Human cytochrome P450 1B1
Reactivity: Human
Clone: 5D3
Host: Mouse
Class: Monoclonal
Alternate name: Aryl hydrocarbon hydroxylase antibody, CP1B antibody, CP1B1_HUMAN antibody, Cyp1b1 antibody, CYPIB1 antibody, Cytochrome P45 1B1 antibody, Cytochrome P45 family 1 subfamily B polypeptide 1 antibody, Cytochrome P45 subfamily I (dioxin inducible) polypeptide 1 (glaucoma 3 primary infantile) antibody, Flavoprotein linked monooxygenase antibody, GLC3A antibody, Microsomal monooxygenase antibody, P451B1 antibody, Xenobiotic monooxygenase antibody
Product description: Monoclonal antibody directed against CYP1B1, a possible anti-cancer target.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Immunogen: Ovalbumin-conjugated synthetic peptide; PENFDPARFLDKDGL (aa. 437-451). Peptide immunogen is identical in mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis familiaris), pig (Sus scrofa) and horse (Equus caballus).
Immunogen Uniprot ID: Q16678
Myeloma used: P3X63Ag8.653
Target background: Cytochrome P450 (CYP) 1B1 is overexpressed in tumour cells and is recognised as a biomarker of the tumour phenotype. Cytochrome P450 1B1 (CYP1B1) is active in the metabolism of oestrogens to reactive catechols and of different procarcinogens. The cytochrome P450 proteins are monooxygenases which catalyse many reactions involved in drug metabolism and the synthesis of cholesterol, steroids and other lipids. Recent studies have highlighted the potential of this enzyme as a novel cancer therapeutic target, resulting in several clinical development programs focused on CYP1B1-activated prodrugs and CYP1B1 inhibitors.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Carnell et al. 2004. Int J Radiat Oncol Biol Phys. 58(2):500-9. PMID: 14751521.

Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue.

Maecker et al. 2003. Blood. 102(9):3287-94. PMID: 12869499.

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.

McFadyen et al. 2001. Br J Cancer. 85(2):242-6. PMID: 11461084.

Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer.

Murray et al. 2001. Annu Rev Pharmacol Toxicol. 41:297-316. PMID: 11264459.

Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1.

McFadyen et al. 1999. J Histochem Cytochem. 47(11):1457-64. PMID: 10544218.

Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151021 Anti-CyclinB1 [V152] Key Info View Tool
151031 Anti-RuvA [RuvA 12C6] Key Info View Tool
151036 Anti-ICAM1 [15.2] Key Info View Tool
151039 Anti-Integrin aVb3 [23C6] Key Info View Tool
151018 Anti-Mos [R38.1] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.